Loading
AMEXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$0.4822
+$0.0042 · +0.88%
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
Previous close
$0.4822
+$0.0042 · +0.88%
After-hours
$0.48
−$0.0022 · -0.46%
Sep 11, 7:04 PM ET
Regular session · ET · Market data may be delayed.
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
Day range
Current $0.4822
52-week range
Current $0.4822
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
48
Fair Value
Sentiment
66
Bullish
Risk
79
High Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
Day range
Current $0.4822
52-week range
Current $0.4822
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 19.19M USD | 19.48M USD | 24.16M USD | 35.4M USD | 44.48M USD |
| Cost of goods sold | 7.22M USD | 8.64M USD | 11.12M USD | 14.9M USD | 15.51M USD |
| Gross profit | 11.97M USD | 10.85M USD | 13.04M USD | 20.5M USD | 28.97M USD |
| Research and development | 33.86K USD | — | — | — | — |
| Selling, general, and administrative | 11.43M USD | 14.04M USD | 22.31M USD | 37.81M USD | 48.58M USD |
| Operating expenses | 14.13M USD | 14.04M USD | 22.31M USD | 37.81M USD | 48.58M USD |
| Interest income | 34.31K USD | — | 63.7K USD | 16.25K USD | — |
| Interest expense | — | 29.51K USD | — | — | 28.93K USD |
| Depreciation and amortization | 1.8M USD | 1.82M USD | 2.93M USD | 2.97M USD | 2.25M USD |
| Operating income | −2.16M USD | −3.19M USD | −9.27M USD | −17.31M USD | −19.62M USD |
| Net income | −2.04M USD | −3.7M USD | −22.94M USD | −70.08M USD | −23.39M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 7, 2025 | 1:8 | — | — |
Stock split | Apr 25, 2023 | 1:45 | — | — |
Effective May 7, 2025
1:8
Effective Apr 25, 2023
1:45
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
